Table I.
Patient characteristics.
| No. | Diagnosis | Age (years) | PSA (ng/ml) | Gleason score | cT | cN | cM |
|---|---|---|---|---|---|---|---|
| 1 | Non-PCa | 54 | 5.4 | - | - | - | - |
| 2 | Non-PCa | 60 | 5.6 | - | - | - | - |
| 3 | Non-PCa | 67 | 5.9 | - | - | - | - |
| 4 | Non-PCa | 67 | 8.1 | - | - | - | - |
| 5 | Non-PCa | 60 | 14 | - | - | - | - |
| 6 | Non-PCa | 69 | 6 | - | - | - | - |
| 7 | Non-PCa | 56 | 8.4 | - | - | - | - |
| 8 | Non-PCa | 61 | 8.6 | - | - | - | - |
| 9 | Non-PCa | 62 | 35.5 | - | - | - | - |
| 10 | Non-PCa | 57 | 5.2 | - | - | - | - |
| 11 | Non-PCa | 64 | 4.4 | - | - | - | - |
| 12 | Non-PCa | 60 | 5.7 | - | - | - | - |
| 13 | Non-PCa | 63 | 11.4 | - | - | - | - |
| 14 | Non-PCa | 65 | 13.2 | - | - | - | - |
| 15 | PCa | 65 | 277 | 4+5 | 4 | 1 | 1 |
| 16 | PCa | 73 | 478 | 4+3 | 3b | 0 | 1 |
| 17 | PCa | 75 | 1,000 | 4+5 | 4 | 1 | 1 |
| 18 | PCa | 79 | 63.2 | 4+5 | 3b | 1 | 1 |
| 19 | PCa | 69 | 95.6 | 4+4 | 4 | 1 | 1 |
| 20 | PCa | 70 | 248 | 3+4 | 3a | 1 | 0 |
| 21 | PCa | 66 | 36.1 | 4+5 | 3a | 1 | 0 |
| 22 | PCa | 81 | 1,338 | 4+5 | 4 | 0 | 1 |
| 23 | PCa | 72 | 102 | 4+4 | 3a | 0 | 0 |
| 24 | PCa | 65 | 212 | 4+4 | 4 | 1 | 1 |
| 25 | PCa | 81 | 11.4 | 4+4 | 2 | 0 | 0 |
| 26 | PCa | 75 | 22.7 | 4+4 | 3b | 0 | 0 |
| 27 | PCa | 73 | 467 | 4+4 | 3b | 1 | 0 |
| 28 | PCa | 58 | 482 | 4+4 | 3b | 1 | 0 |
| 29 | PCa | 73 | 76.4 | 4+4 | 3a | 0 | 0 |
| 30 | CRPC liver metastasis | 64 | 4,100 | 4+5 | 3b | 0 | 1b |
| 31 | CRPC lymph node metastasis | ||||||
| 32 | CRPC bone metastasis | ||||||
| 33 | CRPC bone metastasis | 75 | 4,690 | 4+5 | 3b | 0 | 0 |
| 34 | CRPC lung metastasis | ||||||
| 35 | CRPC liver metastasis | 78 | 3,850 | 3+5 | 4 | 0 | 1b |
| 36 | CRPC dural metastasis | ||||||
| 37 | CRPC bone metastasis |
PSA, prostate-specific antigen; PCa, prostate cancer; CRPC, castration-resistant prostate cancer.